Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised options to acquire 1,500 shares of Common Stock at $8.43 per share and sold 1,500 shares in an open-market transaction at $34.02 per share.
The filing shows he continues to hold 116,731 Common Stock shares directly and 20,000 shares indirectly through a trust, as well as 69,681 remaining stock options after the exercise. The transactions were carried out under a Rule 10b5-1 trading plan adopted on December 26, 2025, indicating they were pre-scheduled rather than discretionary.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 1,500 shares ($51,030)
Net Sell
4 txns
Insider
Pande Atul
Role
null
Sold
1,500 shs ($51K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 1,500 | $0.00 | -- |
| Exercise | Common Stock | 1,500 | $8.43 | $13K |
| Sale | Common Stock | 1,500 | $34.02 | $51K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 69,681 shares (Direct, null);
Common Stock — 118,231 shares (Direct, null);
Common Stock — 20,000 shares (Indirect, By Trust)
Footnotes (1)
- Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested. The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option.
Key Figures
Shares sold: 1,500 shares
Sale price: $34.02/share
Options exercised: 1,500 shares
+4 more
7 metrics
Shares sold
1,500 shares
Common Stock sold at $34.02 per share on June 15, 2026
Sale price
$34.02/share
Open-market sale of 1,500 Common Stock shares
Options exercised
1,500 shares
Stock options exercised at $8.43 per share
Exercise price
$8.43/share
Stock Option (right to buy) for Common Stock
Direct holdings after
116,731 shares
Common Stock directly owned following transactions
Indirect holdings after
20,000 shares
Common Stock held indirectly by trust
Remaining options
69,681 options
Stock Option (right to buy) remaining after 1,500 exercised
Key Terms
Rule 10b5-1 Plan, stock options, Stock Option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
stock options financial
"Reflects an award of stock options to purchase Common Shares that is fully vested"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 8.4300"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"direct_or_indirect": "I", "nature_of_ownership": "By Trust""
FAQ
What did Immunovant (IMVT) director Atul Pande report in this Form 4?
Director Atul Pande reported exercising options for 1,500 Immunovant shares at $8.43 and selling 1,500 shares at $34.02. The filing also updates his remaining direct, indirect, and option holdings.
What stock options did Atul Pande exercise in Immunovant (IMVT)?
He exercised stock options covering 1,500 Immunovant Common Stock shares at an exercise price of $8.43 per share. The options are fully vested and relate to a grant expiring on November 19, 2029.
What are Atul Pande’s remaining Immunovant (IMVT) holdings after these transactions?
After the reported transactions, he holds 116,731 Immunovant Common Stock shares directly and 20,000 shares indirectly through a trust. He also has 69,681 stock options remaining from the specific option grant described.
Did this Form 4 correct any prior disclosure about Immunovant (IMVT) options?
Yes. It notes a prior Form 4 on May 20, 2026 overstated remaining options by including all options. The updated figure, 69,681 options, reflects only the remaining options for this specific grant.